Printer Friendly

JC virus/human immunodeficiency virus 1 co-infection in the Brazilian Amazonian region.

Introduction

Polyomaviruses are small agents which infect a variety of species including man, non-human primates, cattle, rodents, rabbits, and birds. Two human polyomaviruses are important pathogens, JC virus (JCV) and BK virus (BKV), as they are able to cause a severe, usually fatal, neurological disease (progressive multifocal leukoencephalopathy, PML) and renal infection in immunosupressed patients, respectively. (1-3) The viruses share approximately 72% of nucleotide homology and a high degree of identity (80%) of amino acid sequence of a capsid protein, VP1.4'5 JCV infects the human host and establishes a persistent replicative cycle (including latency) following the acute infection, which favors its dissemination within human populations and its carriage through generations.

Although JCV is found to infect more than 70% of the adult human population as a productively persistent infection, PML is a rare disease. (5-9) It is a manifestation that follows malignant conditions, as well as a consequence of primary or secondary immunodeficiencies, particularly in acquired immunodeficiency syndrome (AIDS). The emergence of human immunodeficiency virus 1 (HIV-1) infection elicited an additional interest in JCV with the frequent finding of HIV-1 carriers co-infected with JCV. (10) The incidence of PML is gradually increasing among AIDS patients, initially as a consequence of the increase of HIV-1 infections, and secondly, as an increase in life expectancy as a result of better antiretroviral drugs. (10) JCV infects HIV-1 carriers and is one of the major opportunistic infections of the central nervous system. (11-15) In our previous study we described JCV and BKV infections among Amerindian tribes, Afro-descendant communities, as well as in the urban area of Belem, state of Para, north of Brazil. (16) The results showed a large genetic variability of strains circulating in the region, infecting a large group of individuals. The presence of European, Asiatic, and African subtypes associated to the ethnic origin of the population samples investigated highlighted the idea that JCV is a good marker for studying the early migration of human populations, reflecting their early and late history.

The present study aimed to describe the occurrence of JCV, including their types and molecular subtypes among HIV-1 carriers and the possible association with neurological disease.

Materials and methods

Population examined

A cross-sectional study was performed, using a convenience sample which included 66 HIV-1 infected persons. A single urine sample was obtained from HIV-1 infected persons residing in the city of Belem, attending the University Hospital Joao de Barros Barreto (HUJBB), for their routine clinical care, and laboratory follow-up determinations of [TCD4.sup.+]/[TCD8.sup.+] lymphocyte counts and HIV-1 plasma viral load (HPVL). All patients were receiving antiretroviral therapy (ART) at the time of sample collection. The duration of ART ranged from one to seven years. Half of them were on ART for no more than five years, with mean and median values of four years. The project was approved by the Ethics Committee of the University Hospital Joao de Barros Barreto (Protocol Number 2092/05). The participants were briefed about the project and those who accepted to take part signed an informed consent. All patients were adults (18 years or older) and were capable to provide answers to a questionnaire which included questions regarding demographic, social and cultural aspects of their life style. The patients were also asked to inform, over common neurological events which are usually considered as baseline symptoms associated to JCV infection, at least once, since their initial diagnosis of HIV-1 infection.

Quantification of HPVL and [TCD4.sup.+]/[TCD8.sup.+] lymphocyte counts

HPVL was determined by the bDNA method (VERSANT[R] HIV-1 RNA 3.0 Assay bDNA "Versant Assay", Siemens, USA) following the manufacturer's directions. Whole blood samples were processed within four hours of collection for the determination of [TCD4.sup.+] counts by flow cytometry (FacsCount, Becton & Dickinson, San Jose, CA, USA) using the FacsCount[TM] Reagents immunomonitoring kit, following the protocol recommended by the manufacturer (Becton Dickinson, San Jose, CA, USA). Both procedures were routinely conducted at the Virology Laboratory, which is one of the National Reference Laboratory for the two determinations.

Urine sample collection and DNA extraction

Urine samples (50 mL) were collected in specific vial collectors and transported to the Virology Laboratory of the Institute of Biological Sciences of the Universidade Federal do Para (ICB/UFPA) and stored at -20[degrees]C until assaying for JCV infection. The urine samples were centrifuged at 5000 rpm for 15 min, the urinary sediment washed three times with sterile saline solution and the cell pellet used for DNA extraction according to the protocol using the EZ-DNA kit (Gentra Systems, Inc., Minneapolis, MN, USA), as previously described. (16)

Molecular analysis

Polymerase chain reaction--PCR was performed for amplification of the VP1 gene (215 bp) and the genomic region IG (610 bp) of JCV, using a thermocycler (Mastercycler Personal, Eppendorf, Germany), and the amplified products were subjected to purification for subsequent sequencing analysis of the nucleotide bases, as previously described. (16)

Sequencing and subtype analysis

The amplified products of the IG region were used for determining genetic relationships among the strains detected and those recorded in Genbank database. The amplified fragments were submitted to a direct sequencing assay (both forward and reverse) according to the protocol of the ABI Prism Dye Terminator Cycle Sequencing Ready Kit (Life Technologies, Foster City, CA, USA) and the products were loaded on the ABI Prism 310 DNA Sequencer (Life Technologies, Foster City, CA, USA). The nucleotide sequences were used together with other JCV sequences available in the Genbank as previously described. (16) Nucleotides sequences obtained in the present study are available in the Genbank databases under the accession numbers KR062063, KR062064 and KR062065 and were submitted to Basic Local Alignment Search Tool--Blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi) aiming to identify the virus subtype.

Statistical analysis

The frequency of HIV-1/JCV co-infection was estimated by direct counting. To determine whether the variables [TCD4.sup.+], [TCD8.sup.+] and HIV-1 viral load followed a normal distribution, D'Agostino's test was used, and the mean values of the laboratory markers were compared using ANOVA. A p-value <0.05 was considered statistically significant using the BioEstat 5.0 software. (17)

Results

JCV infection was investigated in 66 urine samples of HIV-1 carriers, outpatients and inpatients, attending the University Hospital. Table 1 shows that most of the patients were male (66.7%), within the age range of 21-50 years old (86.4%).

Amplification of VP1 was obtained in 21 (32%) samples (18 males and 3 females) and 11 of them amplified the two regions, VP1 and IG. Sequencing of nine samples from IG region submitted to Basic Local Alignment Search Tool Blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi) were identified as belonging to type B, subtype Af2, with 100% identity, confirming the JCV/HIV-1 co-infection. The molecular analysis also showed the amplification of a nucleotide sequence of 541 bp, characteristic of BKV polyomavirus, showing 97.4% identity with KOM-3 line and a co-infection BKV/HIV-1 in 1.5%.

[TCD4.sup.+] and [TCD8.sup.+] lymphocyte counts and HPVL (Fig. 1) were compared between the mono-infected (HIV-1 only) and co-infected (JCV/HIV-1) patients. The average counts of [TCD4.sup.+] were 130.61 and 105.25 cells/mL (p = 0.5649), and the values for [TCD8.sup.+] were 589.97 and 679.66 cells/mL (p = 0.2416), respectively. The mean values for HPVL ([log.sub.10]) were 4.563 and 4.867 (p = 0.5605), respectively (Fig. 1).

Neurological events were investigated regarding the presence of seizures, as well as, hearing and vision losses (Table 2). The presence of these baseline symptoms at least once after laboratory diagnosis of HIV-1 infection were admitted by 46.3% and 52.6%, of the mono and double infected individuals, respectively, but the difference between the frequencies was not significant (p = 0.860).

Discussion

The information obtained from HIV-1 carriers were sufficient to establish the socio demographic variables and indicate possible trends of the infection. The age range observed (20-60 years) was in agreement with the epidemic in Brazil. (18) Similar results were seen in the USA with patients with non-Hodgkin's lymphoma, HIV-1 negative patients, (19) and healthy Koreans. (20-23) It is believed that JCV infection occurs early in life and therefore it is necessary to monitor the upsurge of disease among healthy individuals or with associated pathologies within different population groups as the virus prevalence is usually high. (5,6,8,9)

Infection was defined by the presence of two codifying genomic regions, VP1 and IG, which have been fairly correlated with seroepidemiological information among different populations. (23-27) The variation of prevalence rates are also commonly observed among HIV-1 carriers. The present work showed 32% prevalence of co-JCV/HIV-1 infection, which is similar to that reported by others among HIV-1 carriers with or without LPM. (7,8,28-32) The search for the virus in other biological fluids including urine, plasma, liquor and cerebral tissue did not increase significantly the prevalence of JCV. (30) Higher prevalence rates have been reported in Brazil in the CSF of HIV-1 carriers, (33) in Germany, in the blood, (34) in France, in brain tissue and blood (35,36) and in Italy, where very high and very low rates were described in the CSF of HIV-1 carriers. (37,38)

Co-infection with BKV is also a commonly reported finding among HIV-1 infected persons. (8,39,40) There was only one BKV/HIV-1 co-infected person in the examined group, in contrast to what has been reported by other. The presence of BKV has been previously reported in our geographical area in Afro-descendants living in the region of Rio Trombetas, Para, (6) among renal patients and the general population of urban centers. (41) The low prevalence of BKV indicates its low levels of dissemination.

HIV-1 infection was more frequent among males, which is consistent with the overall epidemic in Brazil. (18) The observation of sex and age distribution of HIV-1 carriers or not, were described by seven laboratories from England and Wales, (7) among aborigenes from Central Africa (pigmies and Bantus), in patients from general hospital in Australia, including immunocompromised persons, (27) and in Brazil (40) but there were no statistically significant differences of prevalence between sexes.

[TCD4.sup.+] and [TCD8.sup.+] lymphocyte counts, as well as, HIV-1 viral load were not different between mono- and double-infected subjects, which is a common finding, (8,39,40,42) suggesting that the frequency of JCV sheddingmay notbe influenced or altered by the immunodeficiency process, but it remains a matter of controversy yet to be defined.

The investigation of possible disease among the examined group was approached by a self-admitted present or past common symptoms of major perception, including seizures, hearing and vision losses. There was no difference between the frequencies found among the mono- and double-infected groups. Although JCV is a major opportunistic infection of the CNS, (11-15,43) PML is not commonly reported in Brazil. (40) Either we are not performing the correct diagnosis of minor and major symptoms of PML, or reactivation of the virus, although a common feature, is without clinical consequences in HIV1 infected persons in the North and Southeast regions of the country.

Until now, there have been few reports of JCV and BKV of either mono-infection or HIV-1 co-infection in Brazil. The results obtained, so far, show a large frequency of excretion of JCV and sometimes of BKV. The clinical consequences of the infections with both viruses should not be ignored and should deserve a deeper look into the actual clinical and epidemiological picture, including the improvement and dissemination of laboratory diagnosis of both infections.

http://dx.doi.org/10.1016Zj.bjid.2016.05.005

ARTICLE INFO

Article history:

Received 14 December 2015

Accepted 10 May 2016

Available online 5 June 2016

Funding

The present study was fully supported by grants from the STD/AIDS and Hepatitis Department, Ministry of Health/UNESCO, and the Brazilian National Council for Scientific and Technological Development (CNPq).

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

We thank the subjects and send them our best wishes.

REFERENCES

(1.) Padgett BL, Walker DL, Zurhein GM, et al. Cultivation of Papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet. 1971;1:1257-60.

(2.) Gardner SD, Field AM, Coleman DV, Hulme B. New human Papovavirus (BK) isolated from urine after renal transplantation. Lancet. 1971;1:1253-7.

(3.) White MK, Khalili K. Polyomaviruses and human cancer: molecular mechanisms underlying patterns of tumorigenesis. Virology. 2004;324:1-16.

(4.) Hale AD, Bartkevioiute D, Dargevioiute A, et al. Expression and antigenic characterization of the major capsid proteins of Human Polyomaviruses BK and JC in Saccharomyces cerevisiae. J Virol Methods. 2002;104:93-8.

(5.) Mcnees AL, White ZS, Zanwar P, et al. Specific and quantitative detection of Human Polyomaviruses BKV, JCV, and SV 40 by real time PCR. J Clin Virol. 2005;34:52-62.

(6.) Gee GV, Manley K, Atwood WJ. Derivation of a JC virus-resistant human glial cell line: implications for the identification of host cell factors that determine viral tropism. Virology. 2003;314:101-9.

(7.) Knowles WA, Sasnauskas K. Comparison of cell culture-grown JC virus (primary human fetal glial cells and the JCI cell line) and recombinant JCV VP1 as antigen for the detection of anti-JCV antibody by haemagglutination inhibition. J Virol Methods. 2003;109:47-54.

(8.) Behzad-Behbahani A, Klapper PE, Vallely PJ, et al. Detection of BK virus and JC virus DNA in urine samples from immunocompromised (HIV-infected) and immunocompetent (HIV-non-infected) patients using polymerase chain reaction and microplate hybridization. J Clin Virol. 2004;29:224-9.

(9.) Ryschkewitsch C, Jensen P, Hou J, et al. Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J Virol Methods. 2004;121:217-21.

(10.) Henmi C, Sawa H, Iwata H, et al. Establishment of an immunoscreening system using recombinant VP1 protein for the isolation of a monoclonal antibody that blocks JC virus infection. Biochem Biophys Res Commun. 2005;327:242-51.

(11.) Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy J Neurovirol. 2002;8:115-21.

(12.) Berger Jr. Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate immunosuppressive conditions. J Neurovirol. 2003;9:38-41.

(13.) D'Arminio-Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol. 2004;55:320-8.

(14.) Vidal JE, Penalva de Oliveira AC, Fink MC, et al. Aids-related progressive multifocal leukoencephalopathy: a retrospective study in a referral center in Sao Paulo, Brazil. Rev Inst Med Trop. 2008;50:209-12.

(15.) Pizaa F, Finkb MC, Nogueira GS, et al. JC virus-associated central nervous system diseases in HIV-infected patients in Brazil: clinical presentations, associated factors with mortality and outcome. Braz J Infect Dis. 2012;16:153-6.

(16.) Cayres-Vallinoto IMV, Vallinoto ACR, Azevedo VN, et al. Human JCV infections as a Bio-Anthropological marker of the formation of Brazilian Amazonian populations. PLoS ONE. 2012;7:E46523, http://dx.doi.org/10.1371/Journal.Pone.0046523.

(17.) Ayres M, Ayres JR, Ayres DL, Santos AS. BIOSTAT 5.0: Aplicacoes Estatisticas nas Areas das Ciencias Biologicas e Medicas. Belem: Sociedade Civil Mamiraua/MCT-CNPq/Conservation International; 2007.

(18.) Ministerio da Saude do Brasil. Boletim Epidemiologico AIDS e DST Ano III--no 1--01a a 26a semanas epidemiologicas janeiro a junho de 2014, ISSN: 1517-1159. www.aids.gov.br.

(19.) Engels EA, Rollison DE, Hartge P, et al. Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma. Int J Cancer. 2005;117:1013-9.

(20.) Agostini HT, Ryschkewitsch CF, Stoner GL. Genotype profile of human polyomavirus JC excreted in urine of immunocompetent individuals. J Clin Microbiol. 1996;34:159-64.

(21.) Chang H, Wang M, Tsai RT, et al. High incidence of JCV viruria in JC-seropositive older individuals. J Neurovirol. 2002;8:447-51.

(22.) Gu Z-Y, Li Q, Si Y-L, et al. Prevalence of BK virus and JC virus in peripheral blood leukocytes and normal arterial walls in healthy individuals in China. J Med Virol. 2003;70:600-5.

(23.) Jeong B-H, Lee K-H, Choi E-K, et al. Genotyping of the JC virus in urine samples of healthy Korean individuals. J Med Virol. 2004;72:281-9.

(24.) Stoner GL, Jobes DV, Cobo MF, et al. JC virus as a marker of human migration to the Americas. Microbes Infect. 2000;2:1905-11.

(25.) Chima SC, Ryschkewitsch CF, Stoner GL. Molecular epidemiology of human polyomavirus JC in the Biaka pygmies and Bantu of Central Africa. Mem Inst Oswaldo Cruz. 1998;93:615-23.

(26.) Sundsfjord A, Osci A, Rosenqvisty H, et al. BK and JC viruses in patients with systemic lupus erythematosus: prevalent and persistent BK viruria, sequence stability of the viral regulatory regions, and nondetectable viremia. J Infect Dis. 1999;180:1-9.

(27.) Whiley DM, Arden KE, Mackay IM, et al. Simultaneous detection and differentiation of human polyomaviruses JC and BK by a rapid and sensitive PCR-Elaha assay and a survey of the JCV subtypes within an Australian population. J Med Virol. 2004;72:467-72.

(28.) Agostini HT, Yanagihara R, Davis V, et al. Asian genotypes of JC virus in native Americans and in a Pacific island population: markers of viral evolution and human migration. Proc Natl Acad Sci USA. 1997;94:14542-6.

(29.) Ferrante P, Caldarelli-Stefano R, Omodeo-Zorini E, et al. Comprehensive investigation of the presence of JC virus in AIDS patients with and without progressive multifocal leukoencephalopathy. J Med Virol. 1997;52: 235-42.

(30.) Pfister LA, Letvin NL, Koralnik IJ. JC virus regulatory region tandem repeats in plasma and central nervous system isolates correlate with poor clinical outcome in patients with progressive multifocal leukoencephalopathy. J Virol. 2001;75:5672-6.

(31.) Lednicky JA, Vilchez RA, Keitel WA, et al. Polyomavirus JCV excretion and genotype analysis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS. 2003;17:801-7.

(32.) Mischitelli M, Fioriti D, Videtta M, et al. Investigation on the role of cell transcriptional factor SP1 and HIV-1 TAT protein in PML onset or development. J Cell Physiol. 2005;204:913-8.

(33.) Fink MCDS, Penalva de Oliveira AC, Milagres FAP, et al. JC virus DNA in cerebrospinal fluid samples from Brazilian AIDS patients with focal brain lesions without mass effect. J Infect. 2006;52:30-6.

(34.) Weber F, Goldmann C, Kramer M, et al. Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol. 2011;49:636-42.

(35.) Jochum W, Weber T, Frye S, et al. Detection of JC virus by anti-VP1 immunohistochemistry in brains with progressive multifocal leukoencephalopathy. Acta Neuropathol. 1997;94:226-31.

(36.) Dubois V, Moret H, Lafon M-E, et al. JC virus genotypes in France: molecular epidemiology and potential significance for progressive multifocal leukoencephalopathy. J Infect Dis. 2001;183:213-7.

(37.) De Luca A, Giancola ML, Ammassari A, et al. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis. 2000;182:1077-83.

(38.) Giri JA, Gregoresky J, Silguero P, et al. Polyoma virus JC DNA detection by polymerase chain reaction in CSF of HIV infected patients with suspected progressive multifocal leukoencephalopathy. Am Clin Lab. 2001;20:33-5.

(39.) Markowitz RB, Thompson HC, Mueller JF, et al. Incidence of BK virus and JC virus viruria in human immunodeficiency virus-infected and uninfected subjects. J Infect Dis. 1993;167:13-20.

(40.) Nali LH, Centrone CC, Urbano PR, et al. High prevalence of the simultaneous excretion of polyomaviruses JC and BK in the urine of HIV-infected patients without neurological symptoms in Sao Paulo, Brazil. Rev Inst Med Trop Sao Paulo. 2012;54:201-5.

(41.) Pires EP, Bernardino-Vallinoto CV, Alves DM, et al. Prevalence of infection by JC and BK Polyomaviruses in kidney transplant recipients and patients with chronic renal disease. Transpl Infect Dis. 2011;13:633-7.

(42.) Matos A, Duque V, Beato S, et al. Characterization of JC human polyomavirus infection in a Portuguese population. J Med Virol. 2010;82:494-504.

(43.) Holman RC, Torok TJ, Belay ED, et al. Progressive multifocal leukoencephalopathy in the United States, 1979-1994: increased mortality associated with HIV infection. Neuroepidemiology. 1998;17:303-9.

Izaura Maria Vieira Cayres-Vallinoto *, Antonio Carlos Rosario Vallinoto, Giselle Priscila dos Anjos Pena, Vania Nakauth Azevedo, Luiz Fernando Almeida Machado, Marluisa de Oliveira Guimaraes Ishak, Ricardo Ishak

Universidade Federai do Para (UFPA), Instituto de Ciencias Biologicas, Laboratorio de Virus, Belem, Para, Brazil

* Corresponding author.

E-mail address: ivallinoto@ufpa.br (I.M. Cayres-Vallinoto).

Caption: Fig. 1--Comparison of the mean values of (A) TCD4+, (B) TCD8+ lymphocyte counts and (C) mean of HIV-1 viral load between HIV-1 and HIV-1/JCV infected patients.
Table 1--Distribution of HIV-1 carriers investigated for
JCV infection according to sex and age.

Age range        Male (%)    Female (%)   Total (%)

11-20             0           1            1
21-30            10           6
31-40            18           9           27
41-50            10           4           14
>50               3           1            4
No information    3           1            4
Total            44 (66.7)   22 (33.3)    66 (100)

Table 2--Frequency of self-admitted neurological
alterations among HIV-1 carriers and co-infected with
JCV.

Clinical symptoms      HIV-1       JCV/HIV-1    Total
                       carriers    coinfected
                       (%)         (%)

With neurological      19 (46.3)   10 (52.6)    29 (48.3)
  symptoms
Without neurological   22 (53.7)    9 (47.4)    31 (51.7)
  symptoms
Total                  41 (100)    19 (100)     60 (100)

[chi square] = 0.031; p = 0.860.
COPYRIGHT 2016 Contexto
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Original article; John Cunningham virus
Author:Cayres-Vallinoto, Izaura Maria Vieira; Vallinoto, Antonio Carlos Rosario; Pena, Giselle Priscila dos
Publication:The Brazilian Journal of Infectious Diseases
Article Type:Report
Date:Jul 1, 2016
Words:3529
Previous Article:Diagnostic-driven antifungal therapy in neutropenic patients using the D-index and serial serum galactomannan testing.
Next Article:Antimicrobial susceptibility of hospital acquired Stenotrophomonas maltophilia isolate biofilms.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters